Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.34 |
| ▸ | TLR2 | O60603 | 3/20 | 0.33 |
| ▸ | NMT2 | O60551 | 2/20 | 0.32 |
| ▸ | NMT1 | P30419 | 2/20 | 0.32 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.31 |
| ▸ | CHRNG | P07510 | 1/20 | 0.31 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.31 |
| ▸ | CHRND | Q07001 | 1/20 | 0.31 |
| ▸ | CCKAR | P32238 | 1/20 | 0.31 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21166941 | 0.92 | GLP1R (0.52) | GLP1RSIRT6SIRT1GRIN1GRIN2A | |
| SCHEMBL24111252 | 0.87 | GLP1R (0.51) | GLP1RSIRT6SIRT1GRIN1GRIN2A | |
| SCHEMBL21349162 | 0.83 | GLP1R (0.51) | GLP1RSIRT6SIRT1TLR2NMT2 | |
| SCHEMBL21166939 | 0.82 | GLP1R (0.55) | GLP1RSIRT6SIRT1TLR2NMT2 | |
| SCHEMBL4517738 | 0.77 | GLP1R (0.54) | GLP1RSIRT6SIRT1GRIN1GRIN2A | |
| SCHEMBL3484885 | 0.77 | GLP1R (0.54) | GLP1RSIRT6SIRT1GRIN1GRIN2A | |
| SCHEMBL24139979 | 0.76 | GLP1R (0.38) | GLP1R | |
| SCHEMBL16326833 | 0.76 | GLP1R (0.53) | GLP1RSIRT6SIRT1GRIN1GRIN2A | |
| SCHEMBL18906906 | 0.76 | GLP1R (0.49) | GLP1RSIRT6SIRT1TLR2 | |
| SCHEMBL18906902 | 0.76 | GLP1R (0.49) | GLP1RSIRT6SIRT1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190274954-A1 | Copositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190274954-A1 | Copositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid | IAPP, GLP1R, INSR | GLP1R 2/4885SIRT6 4084/4885SIRT1 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.